Genovis Signs Exclusive Distribution Agreement with Sigma-Aldrich® for Sales in Asia, Southeast Asia and South America

Genovis announced today that it has signed an exclusive distribution agreement
with Sigma-Aldrich (http://www.sigma-aldrich.com) Corporation (NASDAQ: SIAL)
that enables the sale of Genovis products in about 50 countries across Asia,
Southeast Asia and South America. The agreement grants exclusive rights in the
countries concerned, and includes existing products in the Genovis protein
engineering portfolio.
“I am extremely pleased that we have signed an agreement with one of the world's
strongest players in supplying the life science community with biochemical and
organic chemical products, kits and services. Our goal is to reach out to the
rapidly growing Asian and South American markets and this is an excellent
solution for us. I am proud that Sigma-Aldrich has elected to include our
products as part of its comprehensive line of products, reagents and kits, and I
look forward to cooperating with the company’s fantastic team, which truly
understands our customers. Together, we have the ability to reach and serve the
many new customers in these markets,” stated Sarah Fredriksson, CEO of Genovis.

Sigma-Aldrich is a leading Life Science and High Technology company whose
biochemical, organic chemical products, kits and services are used in scientific
research, including genomic and proteomic research, biotechnology,
pharmaceutical development, the diagnosis of disease and as key components in
pharmaceutical, diagnostics and high technology manufacturing.
For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel:
4646 -101235 sarah.fredriksson@genovis.com
ABOUT GENOVIS

Genovis develops and sells innovative technologies from two unique product
portfolios. The first includes enzymes that facilitate development and quality
control for applications such as antibody-based drugs. The products launched to
date are aimed at customers who work with development of drugs, new diagnostic
methods and basic research.

The second consists of nanotechnology in new contrast agents and focuses on
design, production and characterization of nanostructures as contrast agents in
medical imaging. The nanostructures and methods that Genovis focuses on can also
be used as carriers of various substances in the development of new drug
delivery methods. The projects are mainly in-house, but also include
collaborations with research groups, including at Lund University.

Genovis shares are listed on the First North OMX Nordic Exchange and Thenberg
Fondkommission is our certified advisor.